S1联合低剂量多西紫杉醇治疗进展期胃癌的临床观察
Study of S1 combined with Docetaxel in patients of advanced gastric cancer
陈艳琼 1刘瑾 1胡会永1
作者信息
- 1. 昆明医科大学曲靖医院曲靖市第一人民医院肿瘤医院 655000
- 折叠
摘要
目的：观察S1联合低剂量多西紫杉醇治疗进展期胃癌的疗效及安全性。方法我院2012年01月-2013年10月共20例进展期胃癌，行s160mg口服 bidd1-14天，多西紫杉醇针40mg/m2静脉滴注 d1治疗，21天重复。2周期评价疗效。结果全组都可评价疗效，中位os12.2月，PFS 5个月，疾病控制率（CR+PR+SD）达40%。主要不良反应为1-2级中性粒细胞减少及1级胃肠反应。结论 S1联合低剂量多西紫杉醇治疗进展期胃癌有效、安全。可作为进展期胃癌的治疗选择。
Abstract
Obejective To evaluate the effect and toxicity of S1 combined with low dose Docetaxel in patients of advanced gastric cancer .methods Twenty patients of advanced gastric cancer were treated with combination therapy of S1 60mg bid on days 1 through 14 plus Docetaxel 40mg/m2 day 1,every 21 days.The evaluation of efficacy and toxicity was achieved in performed after every 2 cycles .Resuit Al 20 patients assessed for efficacy and toxicity. The disease control was 40%,The common toxicities of the regimen included myelosuppression and gastrointestinal reactions.Conclusions The regimen of S1 plus Docetaxel is effective against advanced gastric cancer with acceptable toxicity.
关键词
s1/多西他赛/联合治疗/进展期胃癌Key words
S1/Docetaxel/Advanced gastric cancer/Comined chemotherapy引用本文复制引用
出版年
2014
NETL
NSTL
万方数据